The Rogosin Institute Susan R. Knafel Polycystic Kidney Disease Center is one of few programs in the country with a broad array of resources dedicated to the diagnosis and management of autosomal dominant polycystic kidney disease (PKD) and its complications .Physicians and researchers of the Center are also working to advance understanding of how PKD develops and, ultimately, to design strategies to prevent its progression and identify new treatments.
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disorder and the fourth most common cause of kidney failure requiring dialysis or transplantation. It accounts for approximately five percent of all end-stage renal disease cases in this country, afffecting approximately one in every 1,000 people, with more than 600,000 afflicted patients in the United States and 12 million worldwide. For each child of an affected parent, there is a 50% chance of inheriting PKD. Despite the fact that PKD is so common, there are currently no specific treatments for it.
The most common complications of chronic kidney disease, hypertension, liver cysts, blood in the urine, kidney stones, cardiovascular disease, stroke, urinary tract infection,, and pain. Signs and symptoms usually first appear when patients are in their 20s or 30s, although the diagnosis is often not identified until later, when abnormal kidney function becomes apparent. However, kidney cysts can appear during fetal development or childhood. Current ADPKD treatment aims to slow progression or prevent ESRD by controlling blood pressure, preventing and treating infections, and optimizing general medical health. Clinical trials of specific drug treatments for ADPKD are ongoing at the Rogosin PKD Center
. At Rogosin’s Susan R. Knafel Polycystic Kidney Disease Center
, a highly experienced staff cares for more than 400 patients with ADPKD. Research at the Center aims to improve understanding of the genetic basis and clinical manifestations of ADPKD, while evaluating potentially effective treatments in clinical trials. This has resulted in improvements in genetic testing that have the potential to lower cost of disease screening.
For information about the Susan R. Knafel Polycystic Kidney Disease Center contact:
Stephanie Donahue, NP 212-746-1591
Warren Bobb, NP 212-746-9114